Regeneron Pharmaceuticals (REGN) Invested Capital (2013 - 2026)

Regeneron Pharmaceuticals has reported Invested Capital for 11 years, with the latest figure at $33.7 billion in Q2 2026.

• On a quarterly basis, Invested Capital rose 5.56% year-over-year to $33.7 billion in Q2 2026; TTM through Jun 2026 was $33.7 billion, a 5.56% increase from a year earlier, with the FY2025 full-year figure at $33.2 billion, up 6.08% from the prior year.
• Invested Capital was $33.7 billion for Q2 2026 at Regeneron Pharmaceuticals, up from $33.4 billion in the prior quarter.
• The five-year high for Invested Capital was $33.7 billion in Q2 2026, with the low at $21.9 billion in Q1 2022.
• Average Invested Capital over 5 years is $28.7 billion, with a median of $29.6 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Invested Capital jumped 56.89% in 2022, then increased 5.22% in 2025.
• Over 5 years, Invested Capital stood at $24.6 billion in 2022, then climbed by 13.43% to $28.0 billion in 2023, then grew by 12.1% to $31.3 billion in 2024, then advanced by 6.08% to $33.2 billion in 2025, then rose by 1.37% to $33.7 billion in 2026.
• The last three Invested Capital figures came in at $33.7 billion (Q2 2026), $33.4 billion (Q1 2026), and $33.2 billion (Q4 2025), per Business Quant data.